Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 15 |
| Active Pipeline (Recruiting Now) | 10 (2) |
| Completed vs Stopped Early | 2 / 0 (0.0%) |
| Median Closed Actual Enrollment | 39 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang | 8 |
| Jilin Cancer Hospital | Changchun | 5 |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07133750 | PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | Phase II | RECRUITING |
| NCT06419621 | PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | Phase III | ACTIVE NOT RECRUITING |
| NCT05844150 | A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC | Phase II | ACTIVE NOT RECRUITING |
| NCT05864105 | PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma | Phase II | COMPLETED |
| NCT05918107 | A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Biotheus Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.